Published Jul 29, 2026, 5:53 PM ET · Updated 3 months ago · 1 source

Goldman-Backed Biotech Attovia Seeks $212.5 Million in US IPO

bloomberg

Original Report

Attovia Therapeutics Inc., an early-stage drug developer focused on immune-mediated diseases with high unmet need, is seeking to raise as much as $212.5 million in a US initial public offering.